TearLab Corp. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
28,990.00
23,722.00
33,229.00
19,920.00
16,101.00
2,251
Depreciation, Depletion & Amortization
1,867.00
2,938.00
3,615.00
3,503.00
1,987.00
1,211
Other Funds
14,838.00
2,649.00
5,333.00
4,333.00
3,269.00
4,955
Funds from Operations
12,285.00
18,135.00
24,281.00
12,084.00
10,845.00
3,915
Changes in Working Capital
949.00
37.00
578.00
432.00
1,189.00
1,253
Net Operating Cash Flow
13,234.00
18,172.00
23,703.00
12,516.00
9,656.00
2,662
Capital Expenditures
2,905.00
2,416.00
3,388.00
1,434.00
989.00
Net Investing Cash Flow
2,905.00
3,816.00
3,388.00
1,434.00
989.00
Issuance/Reduction of Debt, Net
-
-
24,393.00
-
-
Net Financing Cash Flow
38,480.00
548.00
24,591.00
15,583.00
2,446.00
Net Change in Cash
22,341.00
21,440.00
2,500.00
1,633.00
8,199.00
Free Cash Flow
16,139.00
20,588.00
27,091.00
13,950.00
10,645.00
Net Assets from Acquisitions
-
1,400.00
-
-
-
Change in Capital Stock
38,480.00
548.00
198.00
15,583.00
2,446.00

About TearLab

View Profile
Address
150 LaTerraza Boulevard
Escondido California 92121
United States
Employees -
Website http://www.tearlab.com
Updated 07/08/2019
TearLab Corp. engages in the development and marketing of lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by testing disease markers in tears at the point-of-care. It also intends to measure the osmolarity of human tears to aid in the diagnosis of dry eye disease in patients suspected of having dry eye disease. The company was founded by Benjamin D.